The ability of HIV-1 to evade the host immune response leads to the establishment of chronic infection. HIV-1 has been reported to up-regulate MHC I molecules on the surface of thymocytes from HIV-1-infected thymus. We demonstrate in this study that HIV-1 up-regulates MHC I on both HIV-1-infected and uninfected thymocytes in a manner that is independent of Nef, proportional to viral replication, and entirely mediated by IFN-␣. IL-3R␣
T he course of HIV-1 disease progression is in large part determined by the quality and quantity of the host antiviral immune response. In particular, long-term nonprogression appears to be critically dependent upon the development of effective and persistent CD4 ϩ and CD8 ϩ T cell responses against HIV-1. To the extent that HIV-1 can evade these responses, viral replication and disease progression can occur.
Among the many mechanisms by which HIV-1 subverts the immune system (see Ref. 1 for review), Nef-mediated down-regulation of MHC class I molecules has been proposed as a means by which infected cells can escape detection by MHC I-restricted CD8 ϩ CTLs (2, 3) . Nef down-regulates MHC I in a manner dependent on conserved residues in the cytoplasmic tail of HLA-A and -B (4 -6). The specificity of Nef for HLA-A and -B allows HIV-infected cells to evade NK cell attack (7) , primarily because NK cells are inhibited by the expression of HLA-C and -E (8).
The above observations are reminiscent of strategies used by other viral pathogens (e.g., adenovirus) to avoid the host immune response (9, 10) . However, it remains unclear whether and to what extent Nef-mediated MHC I down-regulation is related to pathologic events as they occur in vivo. In fact, and in apparent contrast to Nef-mediated effects in immortalized cell lines and in isolated PBMC, HIV-1 infection of the human thymus has instead been associated with MHC I up-regulation (11) . These experiments, conducted in the human thymus implant of the SCID-hu Thy/Liv mouse, showed distinct up-regulation of MHC I expression on the cell surface of thymocytes. Furthermore, increased MHC I expression correlated with the degree of thymocyte depletion, indicating that MHC I up-regulation is directly related to HIV-1 pathogenesis.
A number of explanations could underlie these discrepant results. First, HIV-1-associated events that occur in thymocytes may be dissimilar from those found in the more mature cells of peripheral lymphoid organs. Second, events that transpire within a hematolymphoid organ such as the thymus may not be reproduced by isolated subpopulations of infected cells maintained in cell culture. Finally, and most trivially, the murine environment of the SCID-hu thymic implant may have unexpected and nonphysiologic consequences on MHC I expression that are unrelated to HIV infection per se.
To explore these findings more completely, we have evaluated the impact of HIV-1 infection on MHC I expression in isolated subpopulations of human thymocytes, in human thymic organ culture, and in the SCID-hu Thy/Liv mouse. Consistent with previous data (12) demonstrating MHC I down-regulation in thymocytes retrovirally transduced with Nef, we observed that Nef is associated with modest, but significant, MHC I down-regulation in productively infected thymocytes. However, MHC I is dramatically up-regulated on most (including uninfected) thymocytes from the HIV-1-infected thymus, both in thymic organ culture and in the SCID-hu Thy/Liv mouse. In these settings, HIV-1 is observed to interact with type 2 predendritic cells (preDC2), 3 thereby inducing IFN-␣ secretion and, indirectly, MHC I up-regulation on IFN-␣␤R-positive thymocytes regardless of whether they are HIV-1 infected. These results indicate that the innate immune response mediates MHC I up-regulation in response to HIV-1 infection of the thymus. generated by transfection of 293T cells with plasmid DNA. Virus stocks for inoculation of SCID-hu Thy/Liv implants were generated by electroporation of PBMCs with NL4-3 and subsequent culture in PBMC blasts over a 4-to 7-day period. Ba-L (National Institutes of Health AIDS Research and Reference Reagent Program, contributed by S. Gartner, M. Popovic and R. Gallo) stocks were generated in monocyte-derived macrophages. Supernatants were collected after 8 days of culture and were frozen as aliquots. Stocks were analyzed for p24 content and were titrated by limiting dilution assay for 50% tissue culture infectious doses (TCID 50 ) (18) .
HIV-1 infection of FTOCs
Thymi were dissected into small (10 mm 3 ) pieces using sterile knives. Thymic pieces were then transferred directly into HIV-1 viral stocks (ϳ10 6 TCID 50 ) or conditioned RPMI 1640 medium from mock-infected PBMC cultures. Fetal thymic organ cultures (FTOCs) were inoculated with virus for 4 h at 37°C in a 5% CO 2 incubator. After inoculation, pieces were transferred to sterile filters (Millipore, Bedford, MA) placed on Gelfoam (Pharmacia-Upjohn, Kalamazoo, MI) rafts in 700 l of Yssel's medium (Gemini Bio-Products, Calabasas, CA) in 24-well plates. HIV-1-infected thymic cultures were incubated 7-8 days, and the medium was changed every 2 days. At the termination of culture, individual thymus pieces were dispersed and washed before staining for FACS analysis. To determine whether preDC2 are infected under these conditions, from HIV-1-infected FTOCs, cultures were rinsed with PBS with 2% FCS (PBS-FBS) and then digested with 0.4 g/ml collagenase and 100 U/ml DNase (Sigma-Aldrich, St. Louis, MO). Digested thymic tissue was disrupted by repeated pipetting and separated over a Ficoll gradient (Sigma, Ref. 15 ). The thymic digest was then stained for p24, IL3R␣, and lineage markers (CD3, CD8, CD14, CD15, CD19, CD20, CD34, CD57) for FACS analysis.
To generate conditioned medium, culture supernatant was removed at the termination of culture and centrifuged at 250 ϫ g for 5 min at 4°C to remove cellular debris. Supernatant was stored at Ϫ20°C until use. Secondary FTOCs were established using tissue from an unrelated donor and the conditioned medium from the primary infected FTOC. Pretreatment of conditioned medium with IFN-␣, -␤, or -␥ neutralizing Abs (BioSource International, Camarillo, CA) was conducted before establishment of secondary culture. Lamivudine (5 M; from National Institutes of Health AIDS Research and Reference Reagent Program) was added to the culture at the initiation of secondary cultures. Secondary culture media were changed at 24 h, and freshly thawed conditioned medium pretreated with the appropriate neutralizing Ab was added. Stored conditioned media were thawed and incubated at 37°C for 30 min with saturating amounts of neutralizing Abs (1000 neutralizing units/ml). Secondary FTOCs were harvested 48 h after the initiation of culture.
HIV-1 infection of SCID-hu Thy/Liv mice
All procedures and practices associated with the use of SCID-hu Thy/Liv mice were approved by the Committee on Human Research or the Committee on Animal Research of the University of California (San Francisco, CA). SCID-hu Thy/Liv mice were generated as previously described (16, 17) and maintained under pathogen-free conditions. Animals in a given cohort were constructed from human fetal tissue from a single donor. Implants were directly inoculated (18) with 50 l of virus (2000 TCID 50 ) or sterile tissue culture medium. Implants were harvested at the indicated time points, placed into sterile PBS-FCS, and dispersed into a single-cell suspension. Thymocytes were then counted and aliquoted for p24 ELISA, branched DNA assay for HIV-1 RNA, and FACS analysis as previously described (19) .
FACS staining and analysis
Dispersed thymocytes from FTOC cultures and SCID-hu Thy/Liv implants were washed, pelleted, and resuspended in 50 l of mAbs diluted in 1 mg/ml human gamma globulin and incubated on ice for 30 min. After incubation, cells were rinsed, pelleted, and resuspended in 200 l of PBS-FCS for immediate FACS analysis. Intracellular staining was performed as follows. After initial staining of surface cell markers, cells were rinsed and pelleted. Pellets were resuspended in 200 l of a solution of 1% paraformaldehyde, 1 mg/ml human gamma globulin, and 0.1% Tween 20 in PBS-FCS. Cells were incubated at room temperature for 1 h in the dark and then rinsed twice and pelleted. Pellets were resuspended in Ab to intracellular p24 diluted in PBS-FCS and stained on ice for 30 min. After incubation, cells were rinsed, pelleted, and resuspended in PBS-FCS for immediate FACS analysis.
Four-color FACS staining was performed with the indicated combinations of the following Abs: KC57 (anti-p24) FITC, CD14-allophycocyanin, and CD56-allophycocyanin (all from Coulter, Hialeah, FL); CD3-FITC, CD8-PerCP, CD123-PE, CXCR4-allophycocyanin, CCR5-allophycocyanin, and CD34-allophycocyanin (all from BD Biosciences, San Jose, CA); anti-HLA-A, -B, -C (pan-MHC I; W6/32)-PE (DAKO, Carpinteria, CA); HLA-A2 PE (One Lambda, Canoga Park, CA; PE-conjugated in our laboratory by C. King); and CD118-PE, CD4-allophycocyanin, CD8-allophycocyanin, CD14-allophycocyanin, CD19-allophycocyanin, and CD20-allophycocyanin (all from Caltag Laboratories, Burlingame, CA).
ELISA
Conditioned media from HIV-1-infected FTOCs were harvested 7 days after inoculation and analyzed using IFN-␣, IFN-␤, or IFN-␥ ELISA kits (BioSource International). Importantly, the IFN-␣ ELISA employed in these studies detected human IFN-␣A, ␣2, ␣A/D, ␣D, ␣K, and ␣4b.
Immunohistochemistry
HIV-1-infected SCID-hu Thy/Liv implants were harvested at designated time points and snap-frozen by immersing tissue suspended in Tissue Freezing Medium (Fisher, Pittsburgh, PA) in isopentane cooled in dry ice. Eight-micrometer sections were cut on a Shandon microtome (Thermo Shandon, Pittsburgh, PA), dried overnight, fixed in a 1/1 acetone/methanol solution, and dried for 30 min at room temperature. Endogenous peroxidase was neutralized by pretreatment with 0.3% H 2 O 2 in 0.3% horse serum in TBS. Sections were then blocked with 10% horse serum in 0.1% saponin-TBS. Primary Ab incubations were conducted at 37°C in 5% CO 2 for 1 h as previously reported for IFN-␣ (20) . Secondary Ab incubations were performed at room temperature with biotin-conjugated anti-mouse Abs (Vector Laboratories, Burlingame, CA). Sections were developed with ABC Elite and diaminobenzidene reagents (Vector Laboratories) and mounted using Crystal Mount (Fisher).
IFN-␣ treatment of HIV-1-infected FTOCs
FTOCs were plated on Gelfoam rafts in 24-well plates and were pretreated overnight with 1000 U/ml IFN-␣ (Schering-Plough, Kenilworth, NJ). The next day, FTOCs were inoculated with HIV-1 as described above. HIV-1-infected FTOCs were plated onto Gelfoam rafts, and IFN-␣ (1000 U/ml) was added at the indicated times after inoculation. Seven days after inoculation FTOCs were harvested and dispersed by repeated pipetting. A portion of the cells were reserved for p24 ELISA analysis, and the remaining cells were stained for FACS analysis with p24-FITC, MHC I-PE, or HLA-A2 PE, CD8-PerCP, and CD4-allophycocyanin.
Assessment of HIV-1 gag DNA in preDC2
Lineage (CD3, CD8, CD14, CD15, CD16, CD19, CD20, CD34, CD57)-negative, IL-3R␣ ϩ CD11c Ϫ preDC2s and CD3 ϩ thymocytes were isolated by sorting on a FACSVantage (BD Biosciences) from FTOCs 7 days after inoculation with NL4-3 or Ba-L. After sorting, cells were pelleted and lysed, and lysates were used as templates for real-time PCR. Mock-infected FTOCs were consistently negative for gag expression. The primers used were as follows: ␤-globin antisense, 5Ј-CCTGGGAGTAGATTGGCCAA; ␤-globin sense, 5Ј-GAAGAGCCAAGGACAGGTACG; gag antisense, 5Ј-TGCTATGTCACTTCCCCTTGG; and gag sense, 5Ј-CCATCAATGAG GAAGCTGCA. The probes used were as follows: gag, 5Ј-FAM-TGCAT GCACTGGATGCAATCTATCCCATT-TAMRA; and ␤-globin, 5Ј-FAM CTGTCATCACTTAGACCTCACCCTGTG-TAMRA. PCR were run on an ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA) using the following parameters: 10 min at 95°C and then 40 cycles of 15 s at 95°C and 60 s at 58°C. Primers and probe pairs were designed using PerkinElmer PrimerExpress software, and data were analyzed using Sequence Detector version 1.6.3 software (both from PerkinElmer, Boston, MA).
Results

MHC I is up-regulated on thymocytes in HIV-1-infected human thymus
Previous experiments have shown that MHC I is up-regulated on thymocytes from HIV-1-infected thymus (11) . FTOCs were infected with Nef ϩ (NL4-3) (21) or Nef Ϫ (NL4-3 Xho) (14) CXCR4(X4)-using HIV-1 isolates. Cultures were harvested 7 days after virus inoculation, and relative levels of infection and MHC I expression were determined by flow cytometry. Compared with thymocytes harvested from mock-infected FTOCs, MHC I expression on thymocytes, as assessed by staining with a pan-MHC I Ab, was increased Ͼ10-fold on the majority of thymocytes after infection with NL4-3 or NL4-3 Xho (Fig. 1, A and B) . MHC I upregulation was observed on both p24
ϩ and p24 Ϫ thymocytes (Fig. 1A ), indicating that MHC I up-regulation was independent of productive HIV-1 infection. Although MHC I up-regulation was observed on most thymocytes, productively infected thymocytes from NL4-3-infected cultures consistently showed significant lowered MHC I expression compared with p24 ϩ thymocytes from NL4-3 Xho-infected cultures (Fig. 1B) , indicating that Nef-mediated MHC I down-regulation can occur to a certain degree within infected cells in the HIV-1 infected thymus. As Nef has been reported to primarily affect HLA-A and -B expression (4), thymocytes from mock-infected and NL4-3-infected thymi were assessed for down-regulation of HLA-A2. As shown in Fig. 1C , HLA-A2 down-regulation occurs in NL4-3-infected thymocytes in a manner similar to that observed with pan-MHC I Ab, with lower levels of expression in p24 ϩ compared with p24 Ϫ cells. Yet, the expression of HLA-A2 on p24 ϩ cells was still significantly higher than that found on cells from mock-infected cultures (Fig. 1, A and D) . Similar results were obtained in infections of SCID-hu Thy/Liv implants (data not shown). These data indicate that HIV-1 infection in the intact thymus induces significant up-regulation of MHC I on both infected and uninfected cells.
MHC I up-regulation strongly correlates with productive HIV-1 infection
In time-course experiments conducted in SCID-hu Thy/Liv mice, MHC I up-regulation was observed as early as 4 days after inoculation with NL4-3 (data not shown). After inoculation with X4-or CCR5 (R5)-using HIV-1, NL4-3 ( Fig. 2A) and Ba-L (Fig. 2B) , respectively, MHC I up-regulation on CD4 ϩ CD8 ϩ thymocytes strongly correlated ( p Յ 0.0001) with markers of productive HIV-1 infection, e.g., HIV-1 p24 protein and RNA (Fig. 2, C-F) . Therefore, up-regulation of MHC I is a direct result of HIV-1 infection of the human thymus and correlates with the degree of productive HIV-1 infection. These data support the idea that MHC I up-regulation correlates with HIV-1 pathogenesis in the thymus, as previously reported (11) .
IFN-␣ mediates MHC I up-regulation in HIV-1-infected thymus
To explore the possibility that a soluble factor is responsible for up-regulation of MHC I on uninfected CD4 ϩ CD8 ϩ double-positive (DP) thymocytes in the HIV-1-infected thymus, we tested whether conditioned medium from HIV-1-infected FTOCs could lead to MHC I up-regulation on thymocytes. Conditioned medium from HIV-1-infected or mock-infected cultures was transferred to freshly plated FTOCs from a different donor in the presence of the nucleoside analog lamivudine (to inhibit infection of the secondary cultures by transferred virus). After 2 days in culture, the level of MHC I expression on DP thymocytes was similar to that observed after primary infection of FTOC (Fig. 3A) , implicating the involvement of a soluble factor.
The IFN family of cytokines has been shown to up-regulate MHC I in a variety of cell types. To determine whether MHC I up-regulation in HIV-1-infected thymus was induced by IFN secretion, conditioned medium from HIV-1-infected FTOCs was assayed for the presence of IFN family members. High levels of IFN-␣ (Fig. 3B) , but not IFN-␤ or -␥ (data not shown), were detected by ELISA in all conditioned medium samples from FTOCs productively infected with either NL4-3 or Ba-L. The level of IFN-␣ in the conditioned media ranged from 1000 to 1500 pg/ml (300 -500 IU/ml) and was proportional to the level of MHC I expression observed in the primary culture (data not shown). Importantly, transfer of cultured medium up-regulated MHC I on thymocytes with kinetics similar to administration of exogenous IFN-␣ (data not shown).
To determine whether the presence of IFN-␣ is responsible for the MHC I up-regulation observed in HIV-1 infection of the thymus, neutralizing Abs against IFN-␣, -␤, and -␥ were added to the conditioned media before transfer to secondary cultures. Up-regulation of MHC I expression was blocked by pretreatment of conditioned media from NL4-3-or Ba-L-infected FTOC with neutralizing Abs against IFN-␣; pretreatment with neutralizing Abs against either IFN-␤ or IFN-␥ had no effect (Fig. 3C ). These data demonstrate that IFN-␣ acts as a soluble mediator of MHC I upregulation on DP thymocytes in both X4-and R5-using HIV-1 infection of the human thymus.
To determine whether DP thymocytes are capable of responding to IFN-␣, expression levels of the IFN-␣␤R (CD118) were evaluated on various subpopulations of thymocytes (Table I) . A gradient of receptor expression was found, with highest levels on early maturational intermediates (intrathymic T progenitor and DP) and lower levels on more mature CD3 ϩ cells that express either CD4 or CD8 (SP4 and SP8 thymocytes, respectively). These levels corresponded to the degree of MHC I up-regulation observed on each subpopulation 40 -46 days after inoculation with Ba-L. Interestingly, very little IFN-␣␤R expression was found on CD3 ϩ peripheral blood T cells, indicating that these cells may not be responsive to IFN-␣.
IL-3R␣ ϩ cells secrete IFN-␣ in response to HIV-1 infection of the human thymus
A subset of immature dendritic cells (known as preDC2, plasmacytoid dendritic cells, or natural IFN-producing cells) has been shown to secrete large amounts of IFN-␣ upon incubation with a wide range of viruses (22, 23) . PreDC2 have been described in the peripheral blood, but also reside in the thymus (24, 25) . To determine whether IL-3R␣ (CD123 ϩ ) preDC2 might be responsible for the production of IFN-␣ in HIV-1-infected thymic tissue, immunohistochemical stains were used to detect IL-3R␣ and IFN-␣ in mock-and HIV-1-infected SCID-hu Thy/Liv implants. In mockinfected animals, large granular IL-3R␣ ϩ cells were observed in the medulla (Fig. 4A ), but these cells did not have detectable levels of IFN-␣ (Fig. 4B) . Twenty-one days after NL4-3 infection, analysis of serial sections indicated that most of the IL-3R␣ ϩ cells were also IFN-␣ ϩ (arrows in Fig. 4, C and D) ; in all cases, the positively staining cells were large, granular, and localized to the thymic medulla. Similar results were obtained in Ba-L-infected animals 42 days after HIV-1 inoculation (data not shown). These data demonstrate that preDC2-like cells resident in the uninfected thymus secrete IFN-␣ after HIV-1 infection.
It was of interest to determine whether preDC2 are infected by HIV-1, as infection of these cells may compromise their function in the innate immune response. Thymic tissue was dispersed with collagenase, and preDC2 were stained for expression of CCR5 and CXCR4, the coreceptors for HIV-1. IL-3R␣ ϩ preDC2 isolated from the human thymus were found to express both CCR5 and CXCR4 (Fig. 4E) as well as CD4 (24, 25) , indicating that they could be permissive for HIV-1 infection. Indeed, thymic preDC2 from HIV-1-infected FTOCs were found to be positive for intracellular p24 by FACS analysis (Fig. 4F) . Furthermore, we found significant HIV-1 DNA in sorted preDC2 from both NL4-3-infected (265 gag copies/1000 sorted cell equivalents; n ϭ 4) and Ba-L-infected (940 gag copies/1000 sorted cell equivalents; n ϭ 4) FTOCs by real-time PCR. These data demonstrate that preDC2 are infected by HIV-1 in the thymus and that both CXCR4-and CCR5-using HIV-1 isolates can infect thymic preDC2. Further study will be necessary to determine what impact HIV-1 infection has on preDC2 function and IFN-␣ secretion. 
IFN-␣␤R MFI
a Immature thymocytes express more IFN-␣␤R and show more up-regulation of MHC I than more mature thymocytes and peripheral blood (PB) T cells. CD3
ϩ PB lymphocytes were isolated from two healthy volunteers and thymocytes were isolated from four fetal thymi and stained for CD3, CD4, CD8, and IFN-␣␤R. Isotype staining was subtracted during analysis. Shown are the average percent positive and mean fluorescence intensities (MFI) of all donors.
b The increased MHC I expression on thymocytes from Ba-L-infected Thy/Liv implants harvested at days 40 -46 after inoculation over identical populations from mock-infected implants in three independent experiments. NA, Not applicable.
Early treatment of FTOCs with IFN-␣ neutralizes HIV infection
IFN-␣ has long been recognized for its potent antiviral effects (26, 27) . IFN-␣ induces resistance to viral replication in cells, increases the expression of MHC I molecules, and activates NK cells to suppress viral replication in many systems. As shown in Table I , some thymocyte subpopulations express high levels of the IFN-␣␤R and may be able to resist viral infection after IFN-␣-mediated activation of intracellular antiviral cascades.
To determine the ability of IFN-␣ secretion to block HIV-1 infection, we treated FTOCs with IFN-␣ at various times after HIV-1 inoculation. IFN-␣ treatment was found to block productive HIV-1 infection, as measured by cell-associated p24 production and intracellular staining for p24 on day 7 (Fig. 5) . There was no significant advantage to pretreatment of FTOCs with IFN-␣, as initiation of treatment up to 4 days after viral inoculation significantly inhibited HIV-1 replication assessed on day 7. These data demonstrate that IFN-␣, if produced early in infection and in sufficient quantities, is capable of blocking productive HIV-1 infection and/or spread.
Discussion
We demonstrate here that MHC I is up-regulated on both infected and uninfected thymocytes from HIV-1-infected thymus as a result of IFN-␣ secretion by preDC2. Such up-regulation occurs even though Nef continues to down-regulate MHC molecules to a certain degree on the surface of infected thymocytes. HIV-1-induced MHC I up-regulation can be completely blocked by addition of neutralizing Abs to IFN-␣. Furthermore, IFN-␣ secretion is tied to productive viral infection, as MHC I up-regulation correlates strongly with markers of active viral replication, such as viral RNA and p24 production. Although IFN-␣ is protective against viral infection, IFN-␣ secretion by preDC2 in HIV-1-infected thymus does not block thymocyte depletion. This indicates that there is an innate immune response to HIV-1 infection in the thymus, but it cannot adequately control HIV-1-induced pathogenesis. In addition, we observed a significant Nef-dependent down-regulation of HLA-A and -B molecules on the surface of productively infected thymocytes. Although we demonstrated that administration of exogenous IFN-␣ is protective against productive viral replication, it is clear from our studies that endogenous production of IFN-␣ by itself is insufficient to impede HIV-1 pathogenesis in the thymus.
The ability to modulate MHC I expression is a common viral immune evasion tactic. Evidence of Nef-mediated down-regulation of MHC I in in vitro systems has led to the hypothesis that Nef may allow HIV-1-infected cells to evade cytotoxic T cell clones specific for viral Ags (2, 3) . Our data show that Nef down-regulates MHC I expression on a population of p24 ϩ thymocytes. These observations demonstrate that HIV-1-associated events, specifically Nef-mediated down-regulation of MHC I, are similar in thymocytes and more mature peripheral cells. There is a lower relative down-regulation of MHC I in infected thymocytes compared to reports using other cell types (2, 3) , which is probably due to the relatively low MHC I expression on thymocytes (28) . However, it is clear from our data that the dominant effect in intact HIV-1-infected thymus is IFN-␣-induced MHC I up-regulation on both HIV-1-infected and uninfected thymocytes. These experiments underscore the possibility that virus-mediated effects are substantially different in intact lymphoid organs than in dispersed cell culture because of the rich network of accessory cells that mediate important events in the innate immune response. Finally, we demonstrate that we can recapitulate responses identical with HIV-1 infection of FTOCs in SCID-hu thymic implants, suggesting that the observations of MHC I up-regulation in this system are physiologically relevant.
Recent data have led to the speculation that preDC2 act as an important link between the innate and adaptive immune systems (29) . It has been shown previously that preDC2 secrete IFN-␣ when cultured in vitro with HIV-1 (20, 30) . This is the first demonstration of in vivo IFN-␣ secretion by preDC2 in response to viral stimulation. In vitro experiments have shown that maturation of preDC2 after initial response to virus results in the secretion of cytokines and the initiation of an adaptive immune response (29) . Additional experiments will be necessary to determine whether preDC2 can perform these functions in the context of thymic viral infection. We additionally demonstrate that thymic preDC2 express the CXCR4 and CCR5 coreceptors and are productively infected by HIV-1. This is the first demonstration that preDC2 are infected by HIV-1 in vivo; additional experiments will be necessary to determine whether preDC2 from the peripheral blood and lymphoid tissue of HIV-1-infected patients are similarly infected. It will also be interesting to determine the effect of HIV-1 infection of preDC2 on continued antiviral responses by these cells.
The role of IFN-␣ in this dynamic system is still somewhat unclear. Exogenous IFN-␣ acts as a potent antiviral when added to HIV-1-infected cultures up to 4 days after initial inoculation. Our attempts to block endogenous IFN-␣ production with neutralizing Abs in FTOCs have been unsuccessful, most likely because of the close proximity of IFN-␣-producing cells and IFN-␣␤R-bearing cells. Since IFN-␣ is secreted after HIV-1 infection and has been shown in model systems to be capable of suppressing viral replication, the question arises as to why endogenous IFN-␣ secretion by preDC2 is not more effective at containing HIV-1 replication. MHC I up-regulation, a direct marker of IFN-␣ secretion by preDC2, instead acts as a direct correlate of viral replication. This dichotomy may reflect a compromise in preDC2 function after HIV-1 infection. It additionally may reflect inadequate or delayed IFN-␣ secretion by preDC2 and/or negative effects of IFN-␣ secretion on thymopoiesis.
IFN-␣-induced MHC I up-regulation may have detrimental effects on thymopoiesis by disrupting the normal selection milieu in HIV-1-infected thymus. Thymic selection is critically dependent on the avidity of the MHC I and the TCR-CD8 coreceptor signaling complex. We observed significant increases in expression of MHC I on the surface of thymocytes and thymic epithelial cells (data not shown), which may negatively impact the avidity interactions critical to the selection of developing thymocytes. Studies using high-avidity murine models of T cell selection have shown that mature selected thymocytes displayed decreased CD8 cell surface density (31, 32) . Decreased cell surface expression of CD8 presumably lowers the overall affinity of the TCR-CD8 signaling complex for its high avidity MHC I ligand, allowing thymocytes to escape negative selection. We observed a similar down-regulation of CD8 on the surface of mature CD3 ϩ CD8 ϩ thymocytes selected in the HIV-1-infected thymus (data not shown), suggesting that MHC I up-regulation may have detrimental effects on thymocyte maturation.
HIV-1 demonstrates an enormous capacity to evade immune system surveillance. We demonstrate here that HIV-1 infection of the human thymus induces MHC I up-regulation on IFN-␣␤R-bearing thymocytes as a result of secretion of IFN-␣ by preDC2. IFN-␣ secretion up-regulates MHC I on infected and uninfected thymocytes, even though Nef-dependent MHC I down-regulation can still be observed to a certain degree on infected cells. Importantly, IFN-␣ secretion is not sufficient to inhibit viral pathogenesis. This is particularly interesting in light of data demonstrating that exogenous IFN-␣ blocks viral p24 production. These data indicate that there may be an additional level of complexity to the interactions between HIV-1 and sentinel cells such as preDC2 that reside in primary lymphoid tissue. They also underscore the ability of the immune response, at least in primary lymphoid tissue, to counteract viral immune evasion mechanisms.
